

The Medicare prescription drug program (Part D): Status report

ISSUE: We present the annual status report of the Part D program.

KEY POINTS: Staff will present information about Part D enrollment in 2017, plan offerings for 2018, and trends in indicators of program operations including drug pricing, aggregate spending levels, access, and quality. Staff will also review materials presented at the November 2017 meeting and present the Commission's draft recommendation related to biosimilars.

ACTION: Commissioners will discuss the material and will vote on the draft recommendation.